Basic Information
| Drug ID | DDPD00643 |
|
| Drug Name | Mebendazole | |
| Molecular Weight | 295.2927 | |
| Molecular Formula | C16H13N3O3 | |
| CAS Number | 31431-39-7 | |
| SMILES | COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C1=CC=CC=C1 | |
| External Links | ||
| DRUGBANK | DB00643 | |
| PubChem Compound | 4030 | |
| PDR | 23975 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 2.83 | - | 2.83 | - | SANGSTER (1994) |
| Melting Point | 288.5 | ℃ | 288.5 | ℃ | PhysProp |
| Water Solubility | 71.3 | mg/L | 71.3 | mg/L | YALKOWSKY,SH & DANNENFELSER,RM 1992) |
| Log S | -3.88 | - | -3.88 | - | ADME Research, USCD |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
|---|---|---|---|---|---|---|
| Absorption | 7.5 | % | 5-10 | % | PO, oral; | DRUGBANK |
| Clearance | 0.90 | L/h/kg | 15 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 1.2 | L/kg | 1.2 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 5.8 | null | 2.5-5.5(2.5-9) | null | normal hepatic function; | DRUGBANK | Half-life | 35.0 | h | ~35 | h | hepatopathy，LD; | DRUGBANK | Half-life | 1.1 | h | 1.1 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Toxicity LD50 | 620.0 | mg/kg | 620.0 | mg/kg | PO, oral; mouse; | DRUGBANK |
| Eliminate Route | 2.0 | % | ~2 | % | Urinary excretion; Male, men; human, homo sapiens; | DRUGBANK | Eliminate Route | 98.0 | % | ~98 | % | Faeces excretion; Male, men; human, homo sapiens; | DRUGBANK |
| Protein Binding | 92.5 | % | 90-95 | % | DRUGBANK |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for children | 500.0 | mg/day | 500 | mg/day | PO, oral | Emverm | mebendazole | PDR |
| Max dose for children | 200.0 | mg/day | 200 | mg/day | PO, oral | Emverm | mebendazole | PDR |
| Max dose for children | 40.0 | mg/day | 40 | mg/day | PO, oral | Emverm | mebendazole | PDR |
| Max dose for children | 500.0 | mg/day | 500 | mg/day | PO, oral | Emverm | mebendazole | PDR |
| Max dose for adolescents | 500.0 | mg/day | 500 | mg/day | PO, oral | Emverm | mebendazole | PDR |
| Max dose for adolescents | 200.0 | mg/day | 200 | mg/day | PO, oral | Emverm | mebendazole | PDR |
| Max dose for adolescents | 40.0 | mg/day | 40 | mg/day | PO, oral | Emverm | mebendazole | PDR |
| Max dose for adults | 500.0 | mg/day | 500 | mg/day | PO, oral | Emverm | mebendazole | PDR |
| Max dose for adults | 200.0 | mg/day | 200 | mg/day | PO, oral; 3-day regimen | Emverm | mebendazole | PDR |
| Max dose for adults | 40.0 | mg/day | 40 | mg/day | PO, oral | Emverm | mebendazole | PDR |
| Max dose for geriatric | 500.0 | mg/day | 500 | mg/day | PO, oral | Emverm | mebendazole | PDR |
| Max dose for geriatric | 200.0 | mg/day | 200 | mg/day | PO, oral; 3-day regimen | Emverm | mebendazole | PDR |
| Max dose for geriatric | 40.0 | mg/day | 40 | mg/day | PO, oral | Emverm | mebendazole | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1